Arcturus Therapeutics Holdings (ARCT) Accumulated Expenses (2018 - 2026)

Arcturus Therapeutics Holdings' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $5.5 million for Q1 2026.

• Quarterly Accumulated Expenses fell 82.03% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (down 82.03% YoY) and the FY2025 annual result came in at $23.9 million, up 79.62% from the prior year.
• Accumulated Expenses was $5.5 million for Q1 2026 at Arcturus Therapeutics Holdings, down from $23.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $32.4 million in Q3 2024 and bottomed at $4.0 million in Q4 2022.
• A 5-year average of $15.0 million and a median of $9.2 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses tumbled 85.1% — and 2023, when it soared 689.52%.
• Arcturus Therapeutics Holdings' Accumulated Expenses stood at $4.0 million in 2022, then surged by 689.52% to $31.9 million in 2023, then sank by 58.27% to $13.3 million in 2024, then jumped by 79.62% to $23.9 million in 2025, then tumbled by 77.02% to $5.5 million in 2026.
• Business Quant data shows ARCT's Accumulated Expenses at $5.5 million in Q1 2026, $23.9 million in Q4 2025, and $5.0 million in Q3 2025.